These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 1982072

  • 1. The role of autophosphorylation in modulation of erbB-2 transforming function.
    Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP.
    New Biol; 1990 Feb; 2(2):187-95. PubMed ID: 1982072
    [Abstract] [Full Text] [Related]

  • 2. erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling.
    Segatto O, Lonardo F, Helin K, Wexler D, Fazioli F, Rhee SG, Di Fiore PP.
    Oncogene; 1992 Jul; 7(7):1339-46. PubMed ID: 1352397
    [Abstract] [Full Text] [Related]

  • 3. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
    Rodrigues GA, Park M.
    Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
    [Abstract] [Full Text] [Related]

  • 4. The amino-terminal region of pp60c-src has a modulatory role and contains multiple sites of tyrosine phosphorylation.
    Espino PC, Harvey R, Schweickhardt RL, White GA, Smith AE, Cheng SH.
    Oncogene; 1990 Mar; 5(3):283-93. PubMed ID: 1690377
    [Abstract] [Full Text] [Related]

  • 5. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.
    Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP.
    New Biol; 1990 Nov; 2(11):992-1003. PubMed ID: 1983208
    [Abstract] [Full Text] [Related]

  • 6. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X.
    Oncogene; 1998 Jun 04; 16(22):2835-42. PubMed ID: 9671404
    [Abstract] [Full Text] [Related]

  • 7. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
    Liu SM, Carpenter G.
    J Cell Physiol; 1993 Nov 04; 157(2):237-42. PubMed ID: 7901224
    [Abstract] [Full Text] [Related]

  • 8. Regulation of the cellular src protein tyrosine kinase: interactions of the carboxyl terminal sequences residing between the kinase domain and tyrosine-527.
    Cobb BS, Parsons JT.
    Oncogene; 1993 Nov 04; 8(11):2897-903. PubMed ID: 7692368
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of carboxyl terminal truncation and point mutations on pp60c-src activities.
    Yaciuk P, Cannella MT, Shalloway D.
    Oncogene Res; 1988 Sep 04; 3(2):207-12. PubMed ID: 2465526
    [Abstract] [Full Text] [Related]

  • 11. Identification of autophosphorylation sites of HER2/neu.
    Hazan R, Margolis B, Dombalagian M, Ullrich A, Zilberstein A, Schlessinger J.
    Cell Growth Differ; 1990 Jan 04; 1(1):3-7. PubMed ID: 1706616
    [Abstract] [Full Text] [Related]

  • 12. Avian pp60c-src is more active when expressed in yeast than in vertebrate fibroblasts.
    Cooper JA, Runge K.
    Oncogene Res; 1987 Jan 04; 1(4):297-310. PubMed ID: 2453017
    [Abstract] [Full Text] [Related]

  • 13. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.
    Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T.
    Mol Cell Biol; 1991 Feb 04; 11(2):833-42. PubMed ID: 1671296
    [Abstract] [Full Text] [Related]

  • 14. Activation of pp60c-src transforming potential by mutations altering the structure of an amino terminal domain containing residues 90-95.
    Potts WM, Reynolds AB, Lansing TJ, Parsons JT.
    Oncogene Res; 1988 Feb 04; 3(4):343-55. PubMed ID: 2465527
    [Abstract] [Full Text] [Related]

  • 15. Phosphorylation of Src mutants at Tyr 527 in fibroblasts does not correlate with in vitro phosphorylation by CSK.
    MacAuley A, Okada M, Nada S, Nakagawa H, Cooper JA.
    Oncogene; 1993 Jan 04; 8(1):117-24. PubMed ID: 7678701
    [Abstract] [Full Text] [Related]

  • 16. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP, Sefton BM.
    Oncogene Res; 1988 Sep 04; 3(2):105-15. PubMed ID: 2465525
    [Abstract] [Full Text] [Related]

  • 17. Activation of pp60c-src tyrosine kinase specific activity in tumor-derived Syrian hamster embryo cells.
    Kanner SB, Parsons SJ, Parsons JT, Gilmer TM.
    Oncogene; 1988 Apr 04; 2(4):327-35. PubMed ID: 2452399
    [Abstract] [Full Text] [Related]

  • 18. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line.
    Lansing TJ, Turk BF, Kanner SB, Gilmer TM.
    Cancer Res; 1997 May 15; 57(10):1962-9. PubMed ID: 9157992
    [Abstract] [Full Text] [Related]

  • 19. Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites.
    Epstein RJ.
    Oncogene; 1995 Jul 20; 11(2):315-23. PubMed ID: 7624146
    [Abstract] [Full Text] [Related]

  • 20. Expression, purification, and characterization of Bacneu. A soluble protein tyrosine kinase domain encoded by the neu-oncogene.
    Myers JN, LeVea CM, Smith JE, Kallen RG, Tung L, Greene MI.
    Receptor; 1992 Jul 20; 2(1):1-16. PubMed ID: 1362129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.